Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanocort proof-of-concept study in peripheral artery disease
NL-OMON37733Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised trial of hydrocortisone and methylprednisolone in atherosclerosis and arteriosclerosis obliterans (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: PEG liposome quantity in atherosclerotic plaque or plaque macrophages. Started May 2012; status: active, not recruiting.
02
Drugs
hydrocortisonemethylprednisolone
03
Conditions
atherosclerosisarteriosclerosis obliterans
Beyond the preview
Go deeper on NL-OMON37733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37733.